Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mark W Drummond"'
Publikováno v:
PLoS Computational Biology, Vol 5, Iss 9, p e1000503 (2009)
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy. Bone marrow studies have shown that this
Externí odkaz:
https://doaj.org/article/a3a728b03e7e499091e3e993abeb518a
Autor:
Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H. Boucher, Aimee Jackson, Rachel S. Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts, Rachel Glover, Erica Harris, Hannah R. Bridges, Luigi Grassi, Alba Rodriguez-Meira, Adam J. Mead, Steven Knapper, Joanne Ewing, Nauman M. Butt, Manish Jain, Sebastian Francis, Fiona J. Clark, Jason Coppell, Mary F. McMullin, Frances Wadelin, Srinivasan Narayanan, Dragana Milojkovic, Mark W. Drummond, Mallika Sekhar, Hesham ElDaly, Judy Hirst, Maike Paramor, E. Joanna Baxter, Anna L. Godfrey, Claire N. Harrison, Simón Méndez-Ferrer
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Pha
Externí odkaz:
https://doaj.org/article/16a1a95232b2462f94a84a299c0e1020
Autor:
Lewis Carpenter, Patrick Rockenschaub, Grace B. Hatton, Sofia D'Abrantes, Edward Sims, Nicholas Scott‐Ram, Aurélie Ducès, Gabrielle Emanuel, Adam J. Mead, Mark W. Drummond, Nadezda Lipunova
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 785-793 (2022)
Abstract There is sparse evidence of how well haematological targets are met in practice for essential thrombocythemia (ET) and polycythaemia vera (PV) patients. Patient data was collected between 2008 and 2020 from two UK NHS Trusts for ET and PV pa
Externí odkaz:
https://doaj.org/article/72d7bd04c7e94405b6a5c3220078eb2a
Autor:
Deepti H. Radia, Jason Gotlib, Mark W. Drummond, Tracy I. George, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Daniel J. DeAngelo, Andreas Reiter
Publikováno v:
Blood. 140:1509-1511
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::877c32faae4a7a28f4e6b31efe586dd2
https://doi.org/10.1182/blood-2022-166986
https://doi.org/10.1182/blood-2022-166986
Autor:
Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher, Aimee Jackson, Christina Yap, Jennifer O'Sullivan, Sonia Fox, Isaak Ailts, Amylou C Dueck, Holly L. Geyer, Ruben Mesa, William Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steve Knapper, Josephine Crowe, Ioannis Koutsavlis, Anna L Godfrey, Siamak Arami, Mark W. Drummond, Jennifer Byrne, Fiona J Clark, Carolyn Mead-Harvey, Joanna E Baxter, Mary Frances McMullin, Adam J Mead
Publikováno v:
Blood. 140:1781-1783
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca732d979475dae0c4db309549d92ae
https://doi.org/10.1182/blood-2022-157273
https://doi.org/10.1182/blood-2022-157273
Autor:
Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott Winton, Hans-Peter Horny, Meera Tugnait, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Jason Gotlib
Publikováno v:
Blood. 140:3932-3934
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b35842025a9abe675ca052303fde0d6
https://doi.org/10.1182/blood-2022-167593
https://doi.org/10.1182/blood-2022-167593
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
Supplementary Table 1. Study stratification and dosing regimen; Supplementary Table 2. p53 target genes examined in this study; Supplementary Table 3. Characteristics of evaluable patients treated at the MTD; Supplementary Table 4. Patient demographi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54f4cc19642954ea5217002d26030405
https://doi.org/10.1158/1078-0432.22460694.v1
https://doi.org/10.1158/1078-0432.22460694.v1
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
The following information describes additional study design criteria and safety considerations used in the phase 1 clinical trial of RG7112 in patients with hematological malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448e7208c04cf15744fde05f7fa0ec5d
https://doi.org/10.1158/1078-0432.22460697.v1
https://doi.org/10.1158/1078-0432.22460697.v1
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
Supplementary Fig. 1. Day 10 dose-mean PK profiles in patients with leukemia; Supplementary Figure 2. RG7112 induces p53-mediated apoptosis in circulating lymphoma cells from a patient with SLL/CLL (810 mg to 1500 mg BID)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ff90eadcc873d56ed29004c7759a71
https://doi.org/10.1158/1078-0432.22460700
https://doi.org/10.1158/1078-0432.22460700
Autor:
Kensuke Kojima, Gwen Nichols, Jianguo Zhi, Ruediger Rueger, Monica Reckner, Steve Middleton, Lori Jukofsky, Peter Bridge, Steven Blotner, Bradford Graves, Gong Chen, Xuelin Huang, Graciela M. Nogueras González, Vivian Ruvolo, Swaminathan Padmanabhan Iyer, Mark Kirschbaum, Paresh Vyas, Mark W. Drummond, Giovanni Martinelli, David Bowen, Leslie Popplewell, Roger Strair, Sarit Assouline, Karen Yee, Kevin R. Kelly, Michael Andreeff
Purpose: RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in patients with hematologic malignancies was conducted.Experimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73b8f506539b36aa97ffa998f3a1ed9f
https://doi.org/10.1158/1078-0432.c.6524571.v1
https://doi.org/10.1158/1078-0432.c.6524571.v1